Cel Sci Corp financial data

Symbol
CVM on NYSE
Industry
Biological Products, (No Diagnostic Substances)
Location
8229 Boone Blvd ., Suite 802, Vienna, VA
State of incorporation
CO
Fiscal year end
September 30
Latest financial report
10-Q - Q4 2024 - Feb 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 116 % -26.9%
Debt-to-equity 127 % +12.4%
Return On Equity -238 % -15.9%
Return On Assets -105 % -8.73%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 74.1M shares +48.3%
Common Stock, Shares, Outstanding 74.1M shares +48.1%
Entity Public Float 100M USD
Common Stock, Value, Issued 731K USD +46.1%
Weighted Average Number of Shares Outstanding, Diluted 65.3M shares +34.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 18.2M USD -14.9%
General and Administrative Expense 8.52M USD -4.04%
Operating Income (Loss) -26.8M USD +11.7%
Net Income (Loss) Attributable to Parent -27.9M USD +10.5%
Earnings Per Share, Diluted -0.11 USD/shares +21.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.14M USD -81.7%
Inventory, Net 1.02M USD -54.6%
Assets, Current 5.86M USD -4.82%
Property, Plant and Equipment, Net 7.59M USD -21.3%
Operating Lease, Right-of-Use Asset 1.44M USD -12.5%
Assets 25.7M USD -10.5%
Accounts Payable, Current 2M USD +74.7%
Accrued Liabilities, Current 622K USD -36.9%
Liabilities, Current 5.48M USD +12.6%
Operating Lease, Liability, Noncurrent 1.37M USD -14.1%
Other Liabilities, Noncurrent 125K USD 0%
Liabilities 14.4M USD -10.4%
Retained Earnings (Accumulated Deficit) -521M USD -5.53%
Stockholders' Equity Attributable to Parent 11.3M USD -10.6%
Liabilities and Equity 25.7M USD -10.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.14M USD +15.3%
Net Cash Provided by (Used in) Financing Activities 4.05M USD +0.01%
Net Cash Provided by (Used in) Investing Activities -33K USD +49.2%
Common Stock, Shares Authorized 600M shares 0%
Common Stock, Shares, Issued 74.1M shares +48.1%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.61M USD +42.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 208K USD -15.1%
Deferred Tax Assets, Valuation Allowance 62.5M USD +4.21%
Deferred Tax Assets, Gross 64.6M USD +3.04%
Operating Lease, Liability 1.6M USD -11.3%
Payments to Acquire Property, Plant, and Equipment 33K USD -36.2%
Lessee, Operating Lease, Liability, to be Paid 2.17M USD -14.2%
Property, Plant and Equipment, Gross 18.2M USD +0.35%
Operating Lease, Liability, Current 226K USD +10.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 277K USD -3.48%
Lessee, Operating Lease, Liability, to be Paid, Year One 287K USD -21.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 566K USD -21.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 285K USD +2.89%
Deferred Tax Assets, Operating Loss Carryforwards 34.7M USD +12.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200K shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 294K USD +3.16%
Additional Paid in Capital 532M USD +5.08%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 31K USD -16.2%
Deferred Tax Assets, Net of Valuation Allowance 62.5M USD +4.21%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%